November 18, 2026 · Mayo Clinic proceedings · DOI: 10.1016/j.mayocp.2026.10.024

SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes.

Listen to this summary

This target trial emulation using TriNetX data asked whether initiating an SGLT2 inhibitor versus metformin as first-line therapy for type 2 diabetes is linked to better cardiorenal and mortality outcomes. In 36,720 propensity-matched pairs, SGLT2 inhibitor initiation was associated with lower risks of MACE (HR 0.88), all-cause mortality (HR 0.73), stroke, cardiac arrest, and acute heart failure, with no significant difference in myocardial infarction or kidney replacement therapy. Because the study is observational, these associations are subject to residual confounding and cannot establish causation.

Fang-Ping Kung, Ching-Fang Tsai, Yu-Tzu Chang

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play